RxDoctor Payments Data

Miranda Bevard, PA

Medical · Smithfield, PANPI 1447852447

Payments from drug & device makers

$10,854in general payments, 2019–2025

Across 721 payments — averaging $15.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • AstraZeneca$1K
  • Boehringer Ingelheim$935
  • GSK$900
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$10,854100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,854 in reported general payments places this provider in the 95th percentile of 2,594 medical providers in Pennsylvania.

See all medical providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$39,512
Medicare patients
174
Services billed
540

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban66$61,590
OzempicSemaglutide48$53,381
MounjaroTirzepatide27$33,516
JardianceEmpagliflozin30$23,637
UbrelvyUbrogepant14$22,739
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$18,377
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$10,856
Stiolto RespimatTiotropium Br/Olodaterol Hcl20$10,007
Repatha SureclickEvolocumab14$7,736
MyrbetriqMirabegron15$7,291
FarxigaDapagliflozin Propanediol12$7,227
XareltoRivaroxaban13$7,138
Breo ElliptaFluticasone/Vilanterol11$4,274
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$2,739
Rosuvastatin Calcium168$1,758

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$493$61,59066 claims
Novo NordiskOzempic$1,436$53,38148 claims
Boehringer IngelheimJardiance, Stiolto Respimat$935$33,64450 claims
Lilly USA, LLCMounjaro$1,415$33,51627 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$900$33,50653 claims
AbbVieUbrelvy$1,865$22,73914 claims
Astellas Pharma US IncMyrbetriq$18$7,29115 claims
AstraZenecaFarxiga$1,030$7,22712 claims
Johnson & JohnsonXarelto$165$7,13813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,594 medical providers in Pennsylvania.

Other medical in Smithfield

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →